clofibric acid has been researched along with Insulin Resistance in 12 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The metabolic syndrome is a clustering of risk factors including central obesity, insulin resistance, dyslipidaemia and hypertension." | 2.43 | Dyslipidaemia, hypercoagulability and the metabolic syndrome. ( Athyros, VG; Kakafika, AI; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (91.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gowdra, VS | 1 |
| Mudgal, J | 1 |
| Bansal, P | 1 |
| Nayak, PG | 1 |
| Manohara Reddy, SA | 1 |
| Shenoy, GG | 1 |
| Valiathan, M | 1 |
| Chamallamudi, MR | 1 |
| Nampurath, GK | 1 |
| Montecucco, F | 1 |
| Mach, F | 1 |
| Robins, SJ | 1 |
| Jonkers, IJ | 2 |
| Smelt, AH | 2 |
| van der Laarse, A | 1 |
| Wierzbicki, AS | 1 |
| Mikhailidis, DP | 2 |
| Wray, R | 1 |
| Huang, JW | 1 |
| Yen, CJ | 1 |
| Chiang, HW | 1 |
| Hung, KY | 1 |
| Tsai, TJ | 1 |
| Wu, KD | 1 |
| Asano, M | 1 |
| Yamada, N | 1 |
| Staels, B | 1 |
| Fruchart, JC | 1 |
| Császár, A | 1 |
| Princen, HM | 1 |
| Kuipers, F | 1 |
| Romijn, JA | 1 |
| Boverhof, R | 1 |
| Masclee, AA | 1 |
| Stellaard, F | 1 |
| Geiss, HC | 1 |
| Parhofer, K | 1 |
| Kakafika, AI | 1 |
| Liberopoulos, EN | 1 |
| Karagiannis, A | 1 |
| Athyros, VG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
8 reviews available for clofibric acid and Insulin Resistance
| Article | Year |
|---|---|
Update on therapeutic strategies to increase adiponectin function and secretion in metabolic syndrome.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim | 2009 |
Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?
Topics: Anticholesteremic Agents; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; | 2003 |
Hypertriglyceridemia: associated risks and effect of drug treatment.
Topics: Adult; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Feeding Behavior; Fish Oil | 2001 |
Drug treatment of combined hyperlipidemia.
Topics: Acute Disease; Clofibric Acid; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hydroxymethyl | 2001 |
[Dyslipidemia management in patients with impaired glucose tolerance].
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholesterol, HDL; Clofibric Acid; Eicosapen | 2005 |
Therapeutic roles of peroxisome proliferator-activated receptor agonists.
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Inflamm | 2005 |
Hypertriglyceridemia, the coronary heart disease risk marker "solved".
Topics: Apolipoprotein C-III; Apolipoproteins C; Clinical Trials as Topic; Clofibric Acid; Coronary Disease; | 2005 |
Dyslipidaemia, hypercoagulability and the metabolic syndrome.
Topics: Adipose Tissue; Adiposity; Animals; Aspirin; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Ac | 2006 |
1 trial available for clofibric acid and Insulin Resistance
| Article | Year |
|---|---|
Fish oil increases bile acid synthesis in male patients with hypertriglyceridemia.
Topics: Bezafibrate; Bile Acids and Salts; Blood Glucose; Body Mass Index; Chenodeoxycholic Acid; Cholestero | 2006 |
3 other studies available for clofibric acid and Insulin Resistance
| Article | Year |
|---|---|
Synthesis, characterization, and preclinical evaluation of new thiazolidin-4-ones substituted with p-chlorophenoxy acetic acid and clofibric acid against insulin resistance and metabolic disorder.
Topics: 2,4-Dichlorophenoxyacetic Acid; Animals; Antioxidants; Blood Glucose; Clofibric Acid; Glucose Metabo | 2014 |
Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function.
Topics: Adiponectin; Aged; Body Mass Index; Clofibric Acid; Coronary Vessels; Diabetes Mellitus; Echocardiog | 2004 |
[Diabetic dyslipoproteinemia].
Topics: Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Type 1; Diabet | 2006 |